How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

723 results for

Cardiovascular rehabilitation

Latest & greatest

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

101. Acute coronary syndromes

1.3 Hyperglycaemia in acute coronary syndromes 19 1.4 Drug therapy for secondary prevention 21 1.5 Coronary revascularisation after an MI 28 1.6 Selected patient subgroups 28 1.7 Communication of diagnosis and advice 28 1.8 Cardiac rehabilitation after an MI 29 1.9 Lifestyle changes after an MI 33 T erms used in this guideline 35 Recommendations for research 36 Key recommendations for research 36 Rationale and impact 41 Dual antiplatelet therapy for acute STEMI intended for primary PCI 41 (...) , TA230 and CG130. This guideline partially replaces TA152 and TA71. This guideline is the basis of QS68, QS99 and QS167. This guideline should be read in conjunction with CG95. Overview Overview This guideline covers the early and longer-term (rehabilitation) management of acute coronary syndromes. These include ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTEMI) and unstable angina. The guideline aims to improve survival and quality of life

2020 National Institute for Health and Clinical Excellence - Clinical Guidelines

102. Canadian Stroke Best Practice recommendations, seventh edition: acetylsalicylic acid for prevention of vascular events

Scientific Document Group. 2016 European Guidelines on cardiovascular disease prevention in clinical prac- tice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2016; 37: 2315-81. 37. Arnett DK, Blumenthal (...) (Semchuk), Uni- versity of Saskatchewan, Saskatoon, Sask.; Division of Neurology (Sharma), Department of Medicine, McMaster University, Hamilton, GUIDELINE CMAJ | MARCH 23, 2020 | VOLUME 192 | ISSUE 12 E311 Ont.; Cardiovascular Division (Udell), Department of Medicine Wom- en’s College Hospital; Peter Munk Cardiac Centre (Udell), Toronto Gen- eral Hospital, University of Toronto, Toronto, Ont.; Divisions Physical Medicine and Rehabilitation) (Mountain) and Neurology (Gubitz), Department of Medicine

2020 CPG Infobase

103. Chronic obstructive pulmonary disease in over 16s: diagnosis and management

of: • a history of cardiovascular disease, hypertension or hypoxia or or • clinical signs such as tachycardia, oedema, cyanosis or features of cor pulmonale Echocardiogram T o assess cardiac status if cardiac disease or pulmonary hypertension are suspected CT scan of the thorax T o investigate symptoms that seem disproportionate to the spirometric impairment T o investigate signs that may suggest another lung diagnosis (such as fibrosis or bronchiectasis) T o investigate abnormalities seen on a chest X-ray T (...) early intervention Assessment for pulmonary rehabilitation Identify candidates for pulmonary rehabilitation Assessment for a lung volume reduction procedure Identify candidates for surgical or bronchoscopic lung volume reduction Assessment for lung transplantation Identify candidates for surgery Dysfunctional breathing Confirm diagnosis, optimise pharmacotherapy and access other therapists Onset of symptoms under 40 years or a family history of alpha-1 antitrypsin deficiency Identify alpha-1

2018 National Institute for Health and Clinical Excellence - Clinical Guidelines

104. Hearing loss in adults: assessment and management

weeks after the hearing aids are fitted, with the option to attend this appointment by telephone or electronic communication if the person prefers. 1.7.2 At the follow-up audiology appointment for adults with hearing aids: ask the person if they have any concerns or questions address any difficulties with inserting, removing or maintaining their hearing aids provide information on communication, social care or rehabilitation support services if needed tell the person how to contact audiology (...) such as cardiovascular disease. Hearing loss may cause dementia either directly (for example, neuroplastic changes caused by hearing deprivation or increased listening demands) or indirectly via social isolation and depression (which are known be associated with cognitive decline and dementia). Conversely, it is possible that cognitive decline has an impact on sensory function (for example, affecting attention and listening skills). Currently, there is no good evidence to show that hearing loss causes dementia

2018 National Institute for Health and Clinical Excellence - Clinical Guidelines

105. Chronic heart failure in adults: diagnosis and management

on the roles of the MDT and collaboration between the MDT and the primary care team. The 2013 cardiovascular disease outcomes strategy also noted that the proportion of people with heart failure who have cardiac rehabilitation was around 4%, and that increasing this proportion would reduce mortality and hospitalisation. This update recommends that all people with heart failure are offered an easily accessible, exercise-based cardiac rehabilitation programme, if this is suitable for them. More information T (...) Cardiac rehabilitation 21 1.10 Palliative care 21 T erms used in this guideline 22 Putting this guideline into practice 23 Context 25 Key facts and figures 25 Current practice 25 More information 25 Recommendations for research 26 1 Diuretic therapy for managing fluid overload in people with advanced heart failure in the community . 26 2 Cardiac MRI versus other imaging techniques for diagnosing heart failure 26 3 The impact of atrial fibrillation on the natriuretic peptide threshold for diagnosing

2018 National Institute for Health and Clinical Excellence - Clinical Guidelines

106. Clinical guide for the management of critical care for adults with COVID-19 during the Coronavirus pandemic v4

and NIV 12 HFNO 13 Intubation 13 Mechanical ventilation 14 Prone positioning 15 Tracheostomy 16 NIV and weaning 16 Extubation 16 Extracorporeal membrane oxygenation (ECMO) 17 Aerosol-generating procedures (AGPs) 17 Corticosteroids 17 Secondary or co-infection 18 6 Management of non-respiratory organ failure 18 Cardiovascular 18 Renal 19 Thromboprophylaxis and treatment of thromboembolus 19 Feeding 20 Liver 20 Neurological 20 Hyperglycaemia 21 7 Further guidance 21 Contents28 October 2020, Version 4 (...) - specialist clinicians looking after critical care patients. ? Attention to the stresses on patients, relatives and staff due to restrictions on hospital and ICU visiting, particularly around end-of-life. 3 Clinical characteristics and specific treatments SARS-CoV-2 infection causing COVID-19 may manifest as: ? Acute severe (15%) /critical illness (5%): - Acute hypoxemic respiratory failure. - Non-respiratory organ dysfunction including: › cardiovascular › renal › cardiac › neurological › hepatic

2020 ICM Anaesthesia COVID-19

107. Guidance on establishing and delivering enhanced perioperative services

, individualised to the patient’s specific needs. In most hospitals, the only environment in which this type of care is available is the critical care unit. However, the majority of postoperative patients, including those at increased risk of adverse outcomes, do not require specific critical care interventions such as invasive ventilation or complex cardiovascular support. Critical Care units are always under pressure from emergency admissions, and now in the COVID-19 era, this pressure is magnified (...) professionals involved in their care during admission to an EPC facility. • To receive information on their role in the perioperative pathway including, where indicated, the need for preoperative lifestyle modification, adherence to treatment for long term conditions, and participation in prehabilitation, postoperative rehabilitation and discharge planning. • To receive information to support their continuing recovery in hospital and in the community. • A COVID-19 compliant pathway. • Equity of access

2020 ICM Anaesthesia COVID-19

108. Clinical guide for the management of critical care for adults with COVID-19 during the Coronavirus pandemic

(typical ARDS) phase 14 Prone positioning 14 Tracheostomy 14 NIV and weaning 15 Extubation 15 Extracorporeal membrane oxygenation (ECMO) 15 Aerosol-generating procedures (AGPs) 16 Corticosteroids 16 Secondary or co-infection 16 6 Management of non-respiratory organ failure 16 Cardiovascular 16 Renal 17 Thromboprophylaxis 18 Gut 18 Feeding 18 Gastroprotection 18 Liver 18 Neuromuscular 18 7 Further guidance 19 Nutrition guidelines 19 After-care needs 19 Contents22 June 2020, Version 3 (...) have been described, probably occurring sequentially: › Atypical viral pneumonitis = hypoxaemia with relatively compliant lungs › Classic acute respiratory distress syndrome (ARDS) = stiff lungs - Non-respiratory organ dysfunction: › cardiovascular failure (>25%) › acute kidney injury (25% needing RRT) › cardiac dysrhythmia (eg sinus tachycardia, AF, bradycardia) › neurological complications › liver dysfunction - Hyper-inflammation syndromes may occur – management uncertain, seek advice from local

2020 ICM Anaesthesia COVID-19

109. 2020 Adult Congenital Heart Disease (previously Grown-Up Congenital Heart Disease) (Management of) Guidelines Full Text available with Trip Pro

heart disease 8 3.2 Organization of care 8 3.3 Diagnostic work-up 13 3.3.1 Echocardiography 15 3.3.2 Cardiovascular magnetic resonance imaging 16 3.3.3 Cardiovascular computed tomography 16 3.3.4 Cardiopulmonary exercise testing 16 3.3.5 Cardiac catheterization 16 3.3.6 Biomarkers 16 3.4 Therapeutic considerations 17 3.4.1 Heart failure 17 3.4.2 Arrhythmias and sudden cardiac death 17 Arrhythmia substrates 17 Assessment in patients with suspected/documented arrythmias and arrythmia (...) recommendations, new recommendations, and new concepts 9 Table 4 Classification of congenital heart disease complexity 13 Table 5 Staff requirements for specialist ACHD centres 15 Table 6 Indications for cardiovascular magnetic resonance imaging in ACHD patients 15 Table 7 Risk estimates for arrhythmic events and bradycardias in ACHD 18 Table 8 Definitions of pulmonary hypertension subtypes and their occurrence in ACHD 21 Table 9 Risk reduction strategies in patients with cyanotic congenital heart disease 25

2020 European Society of Cardiology

110. 2020 Atrial Fibrillation (Management of) Guidelines

Postoperative anticoagulation after surgery for atrial fibrillation 52 Long-term antiarrhythmic drug therapy for rhythm control 52 Antiarrhythmic drugs 52 10.3 ‘C – Cardiovascular risk factors and concomitant diseases: detection and management 58 10.3.1 Lifestyle interventions 58 Obesity and weight loss 58 Alcohol and caffeine use 59 Physical activity 59 10.3.2 Specific cardiovascular risk factors/comorbidities 59 Hypertension 59 Heart failure (...) (cardiovascular risk factors and comorbid conditions management)] ABC-bleeding Age, Biomarkers (haemoglobin, cTnT hs T, GDF-15), and Clinical history (prior bleeding) ABC-stroke Age, Biomarkers, Clinical history (stroke risk score) ACS Acute coronary syndromes ACTIVE W Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events trial AF Atrial fibrillation AFFIRM Atrial Fibrillation Follow-up Investigation of Rhythm Management AFL Atrial flutter AHRE Atrial high-rate episode AMICA

2020 European Society of Cardiology

111. 2020 Acute Coronary Syndromes (ACS) in Patients Presenting without Persistent ST-Segment Elevation (Management of) Guidelines Full Text available with Trip Pro

-ST-segment elevation acute coronary syndrome (Supplementary Data) 47 9.1 Lifestyle management (Supplementary Data) 47 9.1.1 Smoking (Supplementary Data) 47 9.1.2 Diet and alcohol (Supplementary Data) 47 9.1.3 Weight management (Supplementary Data) 47 9.1.3 Physical activity (Supplementary Data) 47 9.1.4 Cardiac rehabilitation (Supplementary Data) 47 9.1.5 Psychosocial factors (Supplementary Data) 47 9.1.6 Environmental factors (Supplementary Data) 47 9.1.7 Sexual activity (Supplementary Data) 47 (...) . Management strategy for non-ST-segment elevation acute coronary syndrome patients. 52 Abbreviations and acronyms ACCOAST Comparison of Prasugrel at the Time of Percutaneous Coronary Intervention or as Pretreatment at the Time of Diagnosis in Patients with Non-ST Elevation Myocardial Infarction ACE Angiotensin-converting enzyme ACS Acute coronary syndromes ACUITY Acute Catheterization and Urgent Intervention Triage strategY ACVC Association for Acute Cardiovascular Care ADP Adenosine diphosphate AF Atrial

2020 European Society of Cardiology

112. ESC Guidance for the Diagnosis and Management of CV Disease during the COVID-19 Pandemic Full Text available with Trip Pro

for transmission, the use of telemedicine is highly desirable especially for vulnerable groups, such as older patients. Additionally, telemedicine provides an opportunity for tele-consultations with different specialists and professionals, thus allowing patients to receive a comprehensive therapeutic approach without moving from home to the outpatient clinic or to the hospital. Also telerehabilitation (or home based rehabilitation with telephone contact with the rehab team) is an option for patients discharged (...) coronavirus disease 2019 ( ) has reached pandemic levels; Patients with cardiovascular ( ) risk factors and established cardiovascular disease ( ) represent a vulnerable population when suffering from ; Patients with cardiac injury in the context of have an increased risk of morbidity and mortality. The causing has reached pandemic levels since March 2020. In the absence of vaccines or curative medical treatment, exerts an unprecedented global impact on public health and health care delivery. Owing

2020 European Society of Cardiology

113. Infection Prevention and Control guidance for Long-Term Care Facilities in the context of COVID-19

reports for COVID-19. COVID-19 is an acute respiratory illness caused by a novel human coronavirus (SARS-CoV-2, called COVID-19 virus), which causes higher mortality in people aged =60 years and in people with underlying medical conditions such as cardiovascular disease, chronic respiratory disease, diabetes and cancer. Long-term care facilities (LTCFs), such as nursing homes and rehabilitative centers, are facilities that care for people who suffer from physical or mental disability, some of who

2020 WHO Coronavirus disease (COVID-19) Pandemic

114. Management of adults with mild COVID-19

of mild COVID-19. PP [Taskforce] LEGEND EBR: Evidence-Based Recommendation CBR: Consensus-Based Recommendation PP: Practice Point Living guidance Not prioritised for reviewDIABETES AND CARDIOVASCULAR DISEASE ACEIs/ARBs RECOMMENDED In patients with COVID-19 who are receiving ACEIs/ARBs, there is currently no evidence to deviate from usual care and these medications should be continued unless contraindicated. EBR [Taskforce] Stopping these medications abruptly can lead to acute heart failure or unstable (...) to assess their ongoing and rehabilitation needs. • Review medications that were stopped or started. PP [Taskforce] Follow up care

2020 National COVID-19 Clinical Evidence Taskforce

115. Acute pain management: scientific evidence (5th Edition)

Acute pain management: scientific evidence (5th Edition) ? ? ? ? Acute Pain Management: Scientific Evidence Australian and New Zealand College of Anaesthetists and Faculty of Pain Medicine ? ? ? Endorsed by: Faculty?of?Pain?Medicine,?Royal?College?of? Anaesthetists,?United?Kingdom?? Royal?College?of?Anaesthetists,? United?Kingdom?? Australian?Pain?Society? Australasian?Faculty?of?Rehabilitation?Medicine? College?of?Anaesthesiologists,?? Academy?of?Medicine,?Malaysia? College (...) . It was approved by the NHMRC and published by the Australian and New Zealand College of Anaesthetists (ANZCA) and its Faculty of Pain Medicine (FPM) in 2005. It was also endorsed by a number of major organisations — the International Association for the Study of Pain (IASP), the Royal College of Anaesthetists (United Kingdom), the Australasian Faculty of Rehabilitation Medicine, the Royal Australasian College of Physicians, the Royal Australasian College of Surgeons, the Royal Australian and New Zealand

2020 National Health and Medical Research Council

116. Guidance for the management of early breast cancer: Recommendations and practice points

with a potentially cardiotoxic treatment, particularly in the context of existing cardiovascular disease or multiple cardiovascular risk factors. Recommendation Generally, age alone should not dictate treatment decisions, however all management decisions for an older patient should consider life expectancy; potential risks versus absolute benefits; treatment tolerance; patient preferences; potential barriers to treatment; polypharmacy; and assessment of functional status, comorbidities, falls, depression (...) of developing lymphoedema and provide relevant information before treatment with surgery or radiation therapy. Practice Point Inform patients and their GPs of potential cardiac risks associated with treatment, the importance of ongoing monitoring and management of cardiac health and cardiovascular risk factors based on their baseline and future risk of cardiac dysfunction, and, encourage a heart-healthy lifestyle. Assessment and referral Practice Point Pay attention to the emotional needs of the person

2020 Cancer Australia

117. Shared follow-up and survivorship care for women with low-risk endometrial cancer: summary of evidence

to many other cancers. 23,1,* ` Due to the relatively high survival rate, there is an increasing number of endometrial cancer survivors. 1 ` Surgery is the primary treatment for endometrial cancer. 2 ` Many women with endometrial cancer have co-morbidities including obesity-related issues, hypertension, diabetes and cardiovascular disease. 3-5 Co-morbidity rates reported for women with uterine cancer include: 59% with hypertension, 34% with obesity, 26% with diabetes and 12% with chronic pulmonary (...) disease. 4 Cardiovascular disease is the leading cause of death for women with localised or low grade endometrial cancer. 21, 22 Endometrial cancer recurrence ` Definitions of low-risk endometrial cancer vary, but low-risk groups commonly include International Federation of Gynecology and Obstetrics (FIGO) stage IA or IB endometrial cancers that are histological grade 1 or grade 2. 6 ` Endometrial cancer has a low recurrence rate overall of approximately 13% and for patients considered low-risk

2020 Cancer Australia

118. Guidance on Competencies for Spinal Cord Stimulation

Guidance on Competencies for Spinal Cord Stimulation July 2020 Guidance on Competencies for Spinal Cord Stimulation2. Spinal cord stimulation (SCS) has been used for more than 40 years for a variety of conditions including pain and cardiovascular problems. SCS has been supported by NICE for treatment of neuropathic pain; however experience in using the therapy for other indications is increasing and techniques of stimulus delivery are still evolving. Outcomes are dependent on a variety (...) selection, screening and preparation for therapy a. physical b. psychological c. social aspects d. balanced assessment of benefits/risks e. comprehensive understanding of alternatives to SCS therapy f. management of patient expectations g. provision of rehabilitative support following SCS insertion 4. Interactions of SCS systems with a. medical/electrical/magnetic equipment e.g. diathermy, physiotherapy equipment b. MRI scanners c. other implanted devices e.g. cardiac pacemakers 5. Follow up care

2020 Faculty of Pain Medicine

119. Clinical triage thresholds in respiratory disease patients in the event of a major surge during the COVID-19 pandemic

of Cardiology, University of Ottawa Heart Institute, Ottawa, ON, Canada; k Pulmonary Hypertension Research Group, Institut universitaire de cardiologie et de pneumologie de Québec, Department of Medicine, Université Laval, QC, Canada; l Adult Cystic Fibrosis Program, St Michael's Hospital, University of Toronto, Toronto, ON, Canada; m Division of Respirology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada; n Department of Medicine, Division of Respirology, Libin Cardiovascular (...) Pulmonary Disease Contributes to the Burden of Health Care Use. Data from the CanCOLD Study. Am J Respir Crit Care Med. 2016;194(3):285-298. doi: 10.1164/rccm.201509-1795OC. 6. Camp PG, Hernandez P, Bourbeau J, et al. Pulmonary rehabilitation in Canada: A report from the Canadian Thoracic Society COPD Clinical Assembly. Can Respir J. 2015;22(3):147-152. doi: 10.1155/2015/369851. 7. Bourbeau J, Bhutani M, Hernandez P, et al. Canadian Thoracic Society Clinical Practice Guideline on pharmacotherapy

2020 Canadian Thoracic Society

120. CCS/CTS Position Statement on Pulmonary Hypertension Full Text available with Trip Pro

CCS/CTS Position Statement on Pulmonary Hypertension Canadian Cardiovascular Society/Canadian Thoracic Society Position Statement on Pulmonary Hypertension - Canadian Journal of Cardiology Go search , P977-992, July 01, 2020 Powered By Mendeley Share on Canadian Cardiovascular Society/Canadian Thoracic Society Position Statement on Pulmonary Hypertension Author Footnotes ‡ These authors are co-primary authors. Naushad Hirani Footnotes ‡ These authors are co-primary authors. Affiliations (...) , Ottawa, Ontario K1Y 4W7, Canada. Tel.: +1-613-696-7274. Affiliations University of Ottawa Heart Institute, Ottawa, Ontario, Canada for the CCS/CTS Pulmonary Hypertension Committee Author Footnotes § See page 989 for Secondary Panel Members. Author Footnotes ‡ These authors are co-primary authors. § See page 989 for Secondary Panel Members. DOI: Abstract The landscape of pulmonary hypertension (PH) has changed significantly since the last Canadian Cardiovascular Society/Canadian Thoracic Society

2020 Canadian Cardiovascular Society


Guidelines – filter by country